![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ipso Ventures | LSE:IPS | London | Ordinary Share | GB00B1GDWB47 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.425 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/9/2011 10:32 | mw102 - What on earth are you on? Electrik - you sound very familar. | ![]() tomboyb | |
16/9/2011 10:31 | I used m instead of k... I tend to use MM for Million and m for thousands (its a US thing!) | ![]() electrick | |
16/9/2011 10:30 | but youve said, if it finds succes in eu market, 1. eu signed it off 2. no competitors for 10years 3. once they start selling, they can expand into a market of 50million, and why wouldnt thery sell as the product is required, and its not the thing for pleasure it improve lives, of children, people will pay alot to get children healthy and well, so margin, cost and eveything else will be very good, like i said elecricx i know what i have heard, he was right about ips yesterday and il justhave to wait until monday if he is right again | mw102 | |
16/9/2011 10:26 | A £1.2 million valuation for a company which is receiving a revenue stream of less than £200k per annum and is demonstating a loss of near £500m per annum is having a few issues.. £500m ? | ![]() tomboyb | |
16/9/2011 10:24 | when I referred to cost I meant the purchase price of the drug... lets face it a royalty on a sale which has no margin is pretty low.... C'mon, surely you can see with the inability to trade this and with the lack of information this is going no where.... it is a company which has some rights to some IP and products... some have started yielding small revenues but on the whole there is very little of substance.... OR if there is it is not possible to place a value on it... A £1.2 million valuation for a company which is receiving a revenue stream of less than £200k per annum and is demonstating a loss of near £500m per annum is having a few issues..... perhaps if the other technologies provide some revenue in the near future a life line may be thrown.. perhaps if the current drug is so successful in the EU and finds a mass market then the royalties will keep the wolves from the door.... but to further expect a valuation of the company at a multi bag level is simply infantile.... if you bought then you ar holding for a while or selling at a loss | ![]() electrick | |
16/9/2011 10:22 | With bitechs -it is very difficult getting any product to market - even when you look at the small biotech companies on AIM. A MUST is a big partner to take it through like the Nasdaq listed one for Buccolum - the market cap for that was in excess of $1.5 billion - - (they have a pipeline of products) Therakind also has a pipeline - One almost already there. | ![]() tomboyb | |
16/9/2011 10:15 | hey i only told what i heard was i wrong about ips when i said rns coming today, guys its up to you, electrick, as they have sold the product already its not there problem for costs they gonna get a large payment, for the 64%, even if there was liable for cost it would be for 36%, and they will recieve royalties for a product that has n compettion for 10 years | mw102 | |
16/9/2011 10:11 | im in the stages of learning english. my main language is Australian. | ![]() oil pump | |
16/9/2011 10:11 | Indeed - remember that this is only capped at £1.4mill - the directors are loaded equity based. The largest shareholder is the founder of the gadget shop and new CEO is Craig Rockford. For me - this is'nt tradeable as the realisation of IPSO companies that may sgnificantly enhance value Versus 1.4mill cap. | ![]() tomboyb | |
16/9/2011 10:06 | the therakind 2011 abbreviated dont detail but there was a substantial change to the co net worth - I am assuming part from a fund raise but remainder from the revenue the initial fee provided... company is not divulging so whether IPSO do detail will be a question for them. Royalty payments would be made from EU sales... determine the market for this drug and if possible the cost / profit of the drug.... a lot of information missing. Othe product suite is okay... interested in the Solar PV technol / services also... but a great P&D from the players here and they should be congratulated! | ![]() electrick | |
16/9/2011 10:05 | rumour on street we getting rns monday, regarding the sum, ips just got to sign some papers before news get released, well as far as ive heard its in millions | mw102 | |
16/9/2011 10:02 | zny idea of numbers involed. If funding needed soon as ii saw sahres were issued at a very large cost to share holders? rgds | ![]() oil pump | |
16/9/2011 09:56 | You need to go back a little to 2010 --- Therakind will receive a significant initial upfront payment and a further milestone payment on the granting of marketing approval for the product. Therakind will also receive royalties on sales of the product in the EU. | ![]() tomboyb | |
16/9/2011 09:52 | IPSO retain a stake and will recieve a significant sum on marketing approval - They will also recieve a % royalty via their 36% owned Therakind - | ![]() tomboyb | |
16/9/2011 09:48 | am i right in thinking that ips sold the drug which has just been approved and taken a small royalty. Are they mad | ![]() oil pump | |
16/9/2011 09:48 | Ah is this todays pump and dump falia I see you are not posting and ramping this now, infact nobody is, topinfo and gang have dumped it ! | ![]() kinghorm23 | |
16/9/2011 09:44 | bought some ntog also moving fast | ![]() falia | |
16/9/2011 08:46 | The consortium hold around 60% of IPS - that leaves 40% free float which is further reduced -- -- There is another DRUG that is is the pipeline for Therakind as well for PAIN but that is a little vague at the moment - Cambridge Meditech has something similiar along the lines of AMS and SUN - dyor - that is 100% owned by IPS-- | ![]() tomboyb | |
16/9/2011 08:33 | Well have a look here cash at bank £6million and Mkt cap £2million with a programme possibly about to enter humantrials | ![]() fairdeal2008 | |
16/9/2011 08:27 | I was wrong about the 3.5pence | ![]() electrick | |
16/9/2011 08:25 | Oh dear, big 2nd wave coming, silly panic sellers will get stung. Same happened and CSB around a year ago, I remember the day, 3 days of massive rises, should happen here also IMO. Holding firm. | ![]() 27macca |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions